论文部分内容阅读
目的了解利奈唑胺和万古霉素治疗医院革兰阳性(G+)球菌下呼吸道感染的疗效。方法回顾性分析我院神经外科重症监护病房(NICU)72例G+球菌下呼吸道感染使用万古霉素和利奈唑胺治疗的临床资料。结果利奈唑胺和万古霉素治疗的临床有效率分别为92.3%(12/13)和86.4%(51/59),细菌学清除率分别为92.3%(12/13)和84.7%(50/59),两药疗效相仿(P>0.05)。结论利奈唑胺和万古霉素治疗严重医院G+球菌下呼吸道感染的疗效相仿,对万古霉素疗效不明显的G+球菌感染或不能耐受万古霉素毒副作用的患者可考虑使用利奈唑胺。
Objective To understand the clinical efficacy of linezolid and vancomycin in the treatment of Gram-positive (G +) bacterial lower respiratory tract infections in hospitals. Methods The clinical data of 72 patients with lower respiratory tract infection of G + cocci in our neurosurgical intensive care unit (NICU) treated with vancomycin and linezolid were retrospectively analyzed. Results The clinical efficacies of linezolid and vancomycin treatment were 92.3% (12/13) and 86.4% (51/59), respectively. The bacteriological clearance rates were 92.3% (12/13) and 84.7% (50 / 59), the two drugs have similar efficacy (P> 0.05). Conclusions Linezolid and vancomycin have similar efficacy in the treatment of lower respiratory tract infections of G + cocci in severe hospitals. Linezolid can be considered in patients with vancomycin-refractory G + cocci infection or inability to tolerate vancomycin.